Literature DB >> 27683035

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.

Marios Dimitriou1, Petter S Woll1,2, Teresa Mortera-Blanco1, Mohsen Karimi1, David C Wedge3,4, Helen Doolittle2, Iyadh Douagi1, Elli Papaemmanuil3,5, Sten Eirik W Jacobsen1,2, Eva Hellström-Lindberg1.   

Abstract

The stem and progenitor cell compartments in low- and intermediate-risk myelodysplastic syndromes (MDS) have recently been described, and shown to be highly conserved when compared to those in acute myeloid leukemia (AML). Much less is known about the characteristics of the hematopoietic hierarchy of subgroups of MDS with a high risk of transforming to AML. Immunophenotypic analysis of immature stem and progenitor cell compartments from patients with an isolated loss of the entire chromosome 7 (isolated -7), an independent high-risk genetic event in MDS, showed expansion and dominance of the malignant -7 clone in the granulocyte and macrophage progenitors (GMP), and other CD45RA+ progenitor compartments, and a significant reduction of the LIN-CD34+CD38low/-CD90+CD45RA- hematopoietic stem cell (HSC) compartment, highly reminiscent of what is typically seen in AML, and distinct from low-risk MDS. Established functional in vitro and in vivo stem cell assays showed a poor readout for -7 MDS patients irrespective of marrow blast counts. Moreover, while the -7 clone dominated at all stages of GM differentiation, the -7 clone had a competitive disadvantage in erythroid differentiation. In azacitidine-treated -7 MDS patients with a clinical response, the decreased clonal involvement in mononuclear bone marrow cells was not accompanied by a parallel reduced clonal involvement in the dominant CD45RA+ progenitor populations, suggesting a selective azacitidine-resistance of these distinct -7 progenitor compartments. Our data demonstrate, in a subgroup of high risk MDS with monosomy 7, that the perturbed stem and progenitor cell compartments resemble more that of AML than low-risk MDS.

Entities:  

Keywords:  azacitidine; cancer stem cells; monosomy 7; myelodysplastic syndrome; myeloid leukemia

Mesh:

Substances:

Year:  2016        PMID: 27683035      PMCID: PMC5341937          DOI: 10.18632/oncotarget.12234

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  46 in total

1.  Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood.

Authors:  Ravindra Majeti; Christopher Y Park; Irving L Weissman
Journal:  Cell Stem Cell       Date:  2007-12-13       Impact factor: 24.633

2.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development.

Authors:  Sergei Doulatov; Faiyaz Notta; Kolja Eppert; Linh T Nguyen; Pamela S Ohashi; John E Dick
Journal:  Nat Immunol       Date:  2010-06-13       Impact factor: 25.606

4.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

Authors:  Austin G Kulasekararaj; Alexander E Smith; Syed A Mian; Azim M Mohamedali; Pramila Krishnamurthy; Nicholas C Lea; Joop Gäken; Coralie Pennaneach; Robin Ireland; Barbara Czepulkowski; Sabine Pomplun; Judith C Marsh; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2013-01-09       Impact factor: 6.998

5.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

6.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.

Authors:  L Nilsson; I Astrand-Grundström; I Arvidsson; B Jacobsson; E Hellström-Lindberg; R Hast; S E Jacobsen
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

7.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Authors:  David C Taussig; Farideh Miraki-Moud; Fernando Anjos-Afonso; Daniel J Pearce; Kirsty Allen; Christopher Ridler; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

8.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

Review 9.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more
  12 in total

1.  SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

Authors:  Teresa Mortera-Blanco; Marios Dimitriou; Petter S Woll; Mohsen Karimi; Edda Elvarsdottir; Simona Conte; Magnus Tobiasson; Monika Jansson; Iyadh Douagi; Matahi Moarii; Leonie Saft; Elli Papaemmanuil; Sten Eirik W Jacobsen; Eva Hellström-Lindberg
Journal:  Blood       Date:  2017-06-20       Impact factor: 22.113

Review 2.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 3.  Monosomy 7/del (7q) in inherited bone marrow failure syndromes: A systematic review.

Authors:  Alex Pezeshki; Shreya Podder; Ralph Kamel; Seth J Corey
Journal:  Pediatr Blood Cancer       Date:  2017-07-14       Impact factor: 3.167

Review 4.  The significance of CUX1 and chromosome 7 in myeloid malignancies.

Authors:  Matthew R M Jotte; Megan E McNerney
Journal:  Curr Opin Hematol       Date:  2022-03-01       Impact factor: 3.284

Review 5.  The International Consensus Classification of acute myeloid leukemia.

Authors:  Olga K Weinberg; Anna Porwit; Attilio Orazi; Robert P Hasserjian; Kathryn Foucar; Eric J Duncavage; Daniel A Arber
Journal:  Virchows Arch       Date:  2022-10-20       Impact factor: 4.535

6.  CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions.

Authors:  Jeremy T Baeten; Weihan Liu; Isabelle C Preddy; Ningxuan Zhou; Megan E McNerney
Journal:  Leukemia       Date:  2022-01-17       Impact factor: 12.883

7.  Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.

Authors:  Molly K Imgruet; Julian Lutze; Ningfei An; Bonnie Hu; Saira Khan; Jeffrey Kurkewich; Tanner C Martinez; Donald Wolfgeher; Sandeep K Gurbuxani; Stephen J Kron; Megan E McNerney
Journal:  Blood       Date:  2021-09-02       Impact factor: 25.476

8.  Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.

Authors:  Alba Rodriguez-Meira; Gemma Buck; Sally-Ann Clark; Benjamin J Povinelli; Veronica Alcolea; Eleni Louka; Simon McGowan; Angela Hamblin; Nikolaos Sousos; Nikolaos Barkas; Alice Giustacchini; Bethan Psaila; Sten Eirik W Jacobsen; Supat Thongjuea; Adam J Mead
Journal:  Mol Cell       Date:  2019-02-12       Impact factor: 17.970

Review 9.  Techniques for detecting chromosomal aberrations in myelodysplastic syndromes.

Authors:  Qibin Song; Min Peng; Yuxin Chu; Shiang Huang
Journal:  Oncotarget       Date:  2017-05-09

10.  Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.

Authors:  Marie Bill; Peter B van Kooten Niekerk; Petter S Woll; Laura Laine Herborg; Anne Stidsholt Roug; Peter Hokland; Line Nederby
Journal:  J Cell Mol Med       Date:  2018-02-07       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.